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Background: Few studies have investigated the blood proteome of inflammatory bowel disease (IBD). We characterized the serum abundance of 
proteins encoded at 163 known IBD risk loci and tested these proteins for their biomarker discovery potential.
Methods: Based on the Human Protein Atlas (HPA) antibody availability, 218 proteins from genes mapping at 163 IBD risk loci were selected. 
Targeted serum protein profiles from 49 Crohn’s disease (CD) patients, 51 ulcerative colitis (UC) patients, and 50 sex- and age-matched healthy 
individuals were obtained using multiplexed antibody suspension bead array assays. Differences in relative serum abundance levels between 
disease groups and controls were examined. Replication was attempted for CD-UC comparisons (including disease subtypes) by including 64 
additional patients (33 CD and 31 UC). Antibodies targeting a potentially novel risk protein were validated by paired antibodies, Western blot, 
immuno-capture mass spectrometry, and epitope mapping.
Results: By univariate analysis, 13 proteins mostly related to neutrophil, T-cell, and B-cell activation and function were differentially expressed in 
IBD patients vs healthy controls, 3 in CD patients vs healthy controls and 2 in UC patients vs healthy controls (q < 0.01). Multivariate analyses 
further differentiated disease groups from healthy controls and CD subtypes from UC (P < 0.05). Extended characterization of an antibody tar-
geting a novel, discriminative serum marker, the laccase (multicopper oxidoreductase) domain containing 1 (LACC1) protein, provided evidence 
for antibody on-target specificity.
Conclusions: Using affinity proteomics, we identified a set of IBD-associated serum proteins encoded at IBD risk loci. These candidate proteins 
hold the potential to be exploited as diagnostic biomarkers of IBD.
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INTRODUCTION
Inflammatory bowel disease (IBD) is an immune-me-
diated disease causing chronic inflammation in the gastro-
intestinal (GI) tract. The disease entity is characterized by 
relapsing course of diarrhea, abdominal pain, and weight loss. 
The prevalence of IBD is approximately 0.5% in the Western 
world, and the prevalence and incidence of the disease entity 
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is increasing globally.1 Crohn’s disease (CD) and ulcerative 
colitis (UC) represent the 2 main subtypes of the disease. The 
precise pathophysiology of IBD remains largely unknown, but 
accumulating evidence suggests that the dysregulated mucosal 
immune response is caused by a loss of tolerance toward gut 
microbiota in genetically susceptible individuals.2
Historically, the influence of genetics was first illustrated 
by high concordance rates in family and twin studies.3 During 
the last decades, large consortium-based meta-analyses of 
genome-wide association studies (GWAS) have dramatically 
increased our knowledge of the genetic architecture of IBD and 
its subtypes CD and UC. These analyses have also revealed that 
the genetic information might contribute to the classification of 
IBD patients into disease-specific subtypes, specifically in rela-
tion to the location of inflammation.4 Interestingly, genetic risk 
effects often appear to be mediated by allelic differences (risk 
vs nonrisk variants) in the modulation of mRNA expression 
(expression quantitative trait loci [eQTLs]).
Even though the identification of genetic risk variants has 
largely improved our understanding of disease mechanisms in 
IBD, many genes and their encoded proteins are still function-
ally uncharacterized. Thus, the pace of protein characterization 
has been slower than that at the genetic level, and the repertoire 
and overall nature of the pool of IBD risk gene products (“IBD 
risk proteome”) still remain largely unknown.
One initiative to increase our understanding of the pro-
teome is the Human Protein Atlas (HPA) project, which aims at 
generating and applying antibodies to study all of the approx-
imately 20,000 human proteins encoded in the genome.5 The 
current version of the HPA (version 15) includes 25,039 anti-
bodies targeting 17,005 proteins, most of which are annotated 
to relative expression data and cell- and tissue-specific localiza-
tion (www.proteinatlas.org).
In the present exploratory study, we took advantage of 
the HPA repository for the characterization of expression of the 
IBD risk proteome in human serum. In particular, we screened 
protein products encoded at IBD risk loci for their potential to 
distinguish IBD patients from healthy individuals and to fur-
ther differentiate between different disease subtypes. We thus 
propose a list of IBD-associated protein targets that may be 
exploited in follow-up studies for future IBD profiling efforts.
METHODS
Study Population
The IBD patients included in this study were obtained 
from a cohort previously described.6 In short, adult patients with 
CD and UC were consecutively recruited at the outpatient IBD 
clinic of Örebro University Hospital, Sweden. After obtaining 
an informed written consent, blood samples were collected, 
and the serum was separated after centrifugation at 2400g for 
6 minutes at room temperature. All serum samples were stored 
as aliquots at −80°C. Diagnosis was based on internationally 
accepted clinical, endoscopic, radiologic, and histologic criteria.7 
Medical notes were scrutinized to classify disease characteristics 
according the Montreal classification.8 A random sample set of 
49 CD patients, 51 UC patients, and 50 healthy blood donors 
(no history of chronic GI disease), matched according to sex 
and age ±5 years (sample set, IBD 1), was selected. In addition, 
33 CD and 31 UC patients were selected to extend the analy-
ses and explore possible differences between subgroups of CD 
and UC patients (sample set, IBD 2). Demographics and clini-
cal characteristics of patients with IBD are reported in Table 1. 
None of the patients were included at disease onset, and only 
a few patients had early IBD, as illustrated by the information 
on disease duration in Table 1. The study was approved by the 
Örebro Regional Ethics Committee (2006/245).
Experimental Strategy
To characterize IBD risk proteome serum expression pro-
files in patients and controls, we applied an affinity proteomic 
analysis targeting proteins encoded at known IBD risk loci.9 
In addition, a small subset of proteins known to be involved 
in inflammation, including neutrophil regulation, was added as 
“experimental controls.”10 Quality assessment was followed by 
data analyses based on univariate and multivariate approaches, 
and a brief  outline is reported in Figure 1.
Antibody Bead Array Assay
Antibody selection and bead coupling
The HPA library (version 15)  was screened to identify 
antibodies targeting any of the 1438 predicted protein products 
encoded at the 163 IBD risk loci (known at the time the study 
was initiated).9 From the 601 thereby identified, final selection 
of antibodies suitable for suspension bead arrays (SBAs) was 
based on availability, binding specificity assessed by protein 
arrays,11 and concentration (>0.05 mg/mL). This yielded a total 
of 343 antibodies directed against 205 unique target proteins, 
corresponding to 104 of the 163 IBD risk loci, which are listed 
in Supplementary Table  1, together with a small “control” 
selection of 22 antibodies directed against 13 known neutro-
phil- and inflammation-associated proteins.
Antibodies were then coupled to magnetic color-coded 
microspheres (MagPlex, Luminex Corp.) and assessed for 
coupling efficiency, and SBAs were generated as previously 
described.12 Rabbit antihuman albumin (Dako) and donkey 
antihuman IgG (Jackson ImmunoResearch Laboratories) anti-
bodies were used as controls for sample transfer, whereas rabbit 
IgG (Jackson ImmunoResearch Laboratories) and bare beads 
served as negative controls.
Sample randomization and bead array processing
Before the analysis, serum samples were randomized 
and distributed into their assigned microtiter plate positions 
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using a liquid handling device (Freedom EVO150, Tecan). 
Serum aliquots were then diluted 1:10 in PBS and labeled using 
NHS-PEO4-biotin (Pierce). The labeled samples were diluted 
1:50 in assay buffer and heat-treated at 56°C for 30 minutes 
before being combined with the suspension bead array. Details 
about this protocol have been described previously.13 Transfer 
of  liquid volumes <5  µL into and between plates was per-
formed with a liquid handling device (CyBi-SELMA, CyBio). 
To avoid location effects because of  the sequential read-out 
of  plates,14 diluted samples were randomized across two 384-
well plates to obtain a similar distribution of  sample sets, age, 
and sex. In addition, each 384-well plate contained 24 samples 
(16 repeated pooled serum samples and 8 samples containing 
only buffer) to assess technical variance. The 2 assay plates 
were processed in parallel. The beads were washed in 1x PBS 
with 1% Tween20 using a plate washer (EL406, Biotek). Lastly, 
median fluorescence intensity (MFI) levels were obtained for 
each antibody-coupled bead using Flexmap 3D instruments 
(Luminex Corp.), accepting a minimum of 35 events for each 
bead ID.
Antibody validation
A description of methods used for antibody validation 
can be found in the Supplementary Data.
TABLE 1. Demographics and Clinical Characteristics of CD and UC Patients
IBD 1 IBD 1 IBD 2 IBD 2
Crohn’s Disease Ulcerative Colitis Crohn’s Disease Ulcerative Colitis
 n = 49 n = 51  n = 31 n = 33 
Male sex, No. (%) 33 (67) 35 (69) 21 (68) 21 (64)
Median (range) age at diagnosis, y 28 (10–54) 30 (5–61) 25 (7–46) 26 (12–65)
Median (range) disease duration, y 20 (0–43) 15 (1–39) 17 (0–36) 10 (0–48)
Disease location, No. (%)
 Ileal (L1) 14 (29) 5 (16)
 Colonic (L2) 14 (29) 15 (48)
 Ileocolonic (L3) 21 (43) 11 (35)
 Upper disease (L4)
Disease behavior, No. (%)
 Nonstricutring, nonpenetrating (B1) 18 (37) 18 (58)
 Stricturing (B2) 21 (43) 9 (29)
 Penetrating (B3) 10 (20) 4 (13)
 Perianal fistulas 6 (12) 7 (23)
Disease extent, No. (%)
 Proctitis (E1) 6 (12) 7 (21)
 Left-sided colitis (E2) 23 (45) 10 (30)
 Extensive colitis (E3) 22 (43) 16 (48)
Clinical disease activity, No. (%)a
 Remission 34 (69) 39 (76) 23 (74) 26 (79)
 Active 14 (29) 12 (24) 8 (26) 7 (21)
Medications, No. (%)b
 5ASA/SASP (local or oral) 8 (16) 25 (49) 3 (10) 16 (48)
 Corticosteroids (local or oral) 7 (14) 8 (16) 6 (19) 7 (21)
 Thiopurines 12 (24) 13 (25) 9 (29) 4 (12)
 Methotrexate 2 (4) 2 (4) 3 (10) 1 (3)
 Anti-TNF 1 (2) 0 (0) 3 (10) 0 (0)
 No drugs 24 (49) 12 (24) 13 (42) 12 (36)
Previous surgical resection, No. (%) 34 (69) 6 (12) 15 (48) 3 (9)
Abbreviations: 5ASA/SASP, 5-aminosalicylates/sulfasalazine; anti-TNF, anti–tumor necrosis factor.
aData on disease activity were not available in 1 patient with Crohn’s disease in IBD 1.
bSome patients were in a combination of different treatments: IBD 1 CD, n = 3; IBD 1 UC, n = 8; IBD 2 CD, n = 6; IBD 2 UC, n = 6.
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Data Processing and Analysis
Data preprocessing
For data evaluation, processing, and analysis, the statisti-
cal environment R15 was used unless otherwise stated. For qual-
ity assessment via calculations of coefficient of variations (CV), 
unprocessed data were employed. Antibodies revealing average 
MFI levels lower than rabbit IgG (negative control) or higher 
than anti-albumin (positive control) were removed. Further 
investigations involved data that were processed with multidi-
mensional MA normalization16 after exclusion of data gener-
ated from sample-free assay buffer, reference sample pools, and 
the removal of outliers based on robust principal component 
analysis.17
Univariate comparisons
For each antibody profile, a linear regression model with 
adjustment for age and sex was used to find profiles that could 
separate IBD patients from healthy controls, CD patients from 
healthy controls, or UC patients from healthy controls in the 
IBD 1 sample set. Comparisons of CD patients vs UC patients 
were performed on both sample sets (IBD 1 and IBD 2), and 
results were merged by a fixed-effects model for meta-analysis 
using the “meta” package in R.18 The q-value approach to false 
discovery rate (FDR) estimation19 was used to account for mul-
tiple testing. To shortlist candidate proteins for comparison of 
patients vs healthy controls, we used an FDR cutoff at q < 0.01, 
whereas a less stringent cutoff  of q < 0.05 was used for compar-
ing UC vs CD.
Multivariate analysis
To identify differentially expressed signatures of proteins, 
a multivariate approach was applied. Multivariate classifica-
tion analysis was implemented as sparse partial least squares 
(sPLS) analysis20 for the same comparisons as in the univariate 
analysis. Data from both sample sets (IBD 1 and IBD 2) were 
merged to obtain a data set large enough for a rigorous double 
cross-validation approach (described below). Data were quan-
tile-normalized using the R package “limma” before analysis.21 
After model fitting, variable importance was calculated as a 
variable importance in projection (VIP) value22 for each protein 
in each of the group comparisons: (1) IBD patients vs healthy 
controls, (2) CD patients vs healthy controls, (3) UC patients 
vs healthy controls, (4) CD patients vs UC patients, (5) colonic 
(L2) CD patients vs UC patients, and (6) ileal (L1/L3) CD 
patients vs UC patients. VIP was calculated for all variables, 
and the analyses were optimized for both the number of vari-
ables and the number of components to use in the respective 
FIGURE 1. Schematic description of study. Target selection was made based on the risk loci GWAS hits (n = 163). Thirteen additional proteins 
involved in inflammation, including neutrophil regulation, were added as “experimental controls.” From these, antibodies available from the Human 
Protein Atlas were selected to compose a targeted SBA. Two sample sets, denoted IBD 1 and IBD 2, were then screened using this bead array. Upon 
data processing, both uni- and multivariate analyses were performed to propose targets of interest. Comparisons of IBD patients and subgroups of 
patients vs healthy controls were performed based on sample set IBD 1, and for comparisons between subgroups of patients, both sample sets (ie, 
IBD 1 and IBD 2) were used.
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prediction model, within the inner cross-validation loop.23, 24 
The prediction models were validated, applying the outer leave-
one-out cross-validation (LOO) approach, and hit rates were 
collected. Significance of the observed LOO hit rates was estab-
lished by resampling analyses, that is, randomly permuting the 
class labels and re-running the double cross-validation analyses 
(including inner loops and optimizations) to be able to calculate 
permutation P values for the observed LOO prediction hit rates 
for the original data.
RESULTS
Data Quality Assessment
At first, we assessed the overall quality of the data and 
determined the coefficient of variation (CV) of each anti-
body in replicated and independent samples. As shown in 
Supplementary Figure 1, the CVs of technical reproducibility 
(tCVs), calculated from the replicated reference sample pools, 
were <10% in 279 of 365 antibodies (76%). A denoted biologi-
cal CV (bCV), describing the variation across all other samples, 
was also calculated. The median tCVs (9%) were substantially 
lower when compared with the bCVs (>37%), indicating that 
the variability in the data set is due to biological differences and 
not technical artifacts. For the subsequent analyses, antibodies 
with tCV <15% were included (n = 355). These antibodies were 
directed against 204 proteins, encoded at 104 genetic risk loci. 
We did not identify any sample outliers when applying robust 
PCA analyses (not shown).
Identification of Differentially Abundant 
Proteins
Univariate analysis
To identify single proteins associated with IBD and 
subtypes of the disease, univariate analyses were performed. 
Using the data set IBD 1, the comparison IBD (CD and UC) 
vs healthy controls yielded significant results for 13 antibod-
ies (Table 2), and the relative abundance of the 4 top-ranking 
antibodies is illustrated in Figure  2A. Similarly, an indepen-
dent comparison of CD patients vs healthy controls resulted 
in significant differences for 3 antibodies, and the correspond-
ing comparison of UC patients vs healthy controls resulted in 
significant differences for 2 antibodies (Table  2, Fig.  2B and 
C). When CD patients and UC patients were compared, using 
the combined data set (IBD 1 and IBD 2), significant results 
were obtained for 2 proteins, namely serum amyloid protein 
A  (SAA) and cAMP responsive element binding protein 5 
(CREB5) (Table 3). The relative abundance of these 2 proteins 
is shown in Figure  3. Almost all antibodies that were identi-
fied when IBD and subtypes of the disease were compared 
represented protein products encoded at the 163 IBD risk loci, 
and only 1 of them (serum amyloid protein A  [SAA]) corre-
sponded to the small “control” selection of known neutrophil- 
and inflammation-associated proteins. No significant results 
were observed for the comparisons of colonic CD (L2) vs UC, 
ileal CD (L1/L3) vs UC, and nonstricturing, nonpenetrating 
CD (B1) vs UC. However, the relative abundance of CREB5 
TABLE 2. Antibodies and Corresponding Proteins With Differential Abundance in Patients With IBD and Subtypes of 
the Disease Compared With Controls, Identified by Univariate Analyses
Comparison Gene Antibody P q
IBD-CTRL LACC1 HPA040150 1.3E-05 3.0E-03
IL2RA HPA054622 4.7E-05 4.0E-03
LACC1 HPA061537 6.1E-05 4.0E-03
LNPEP HPA043642 6.8E-05 4.0E-03
CNTF HPA046534 9.1E-05 4.1E-03
LPXN HPA061441 1.0E-04 4.1E-03
BTNL2 HPA039844 1.9E-04 6.1E-03
IFNAR2 HPA029229 2.2E-04 6.1E-03
CARD11 HPA052984 2.3E-04 6.1E-03
JAK2 HPA058253 3.8E-04 8.6E-03
PEX13 HPA061468 4.0E-04 8.6E-03
SLC22A5 HPA063062 5.4E-04 9.8E-03
IFNG HPA063125 5.4E-04 9.8E-03
CD-CTRL LACC1 HPA040150 1.8E-05 2.1E-03
SAA HPA059733 2.0E-05 2.1E-03
LNPEP HPA043642 1.2E-04 8.4E-03
UC-CTRL CNTF HPA046534 8.3E-05 7.8E-03
LPXN HPA061441 8.9E-05 7.8E-03
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FIGURE 2. Candidate proteins: IBD patients vs healthy controls. The boxplots show the top 4 proteins revealing significant differences in univariate 
group comparisons (q < 0.01). A, Candidate proteins to differ between IBD patients (gray; n = 100) and healthy controls (CTRL; white; n = 50) are 
targeted by 2 LACC1 antibodies and shown on the upper panel: HPA040150 (q = 0.003) and HPA061537 (q = 0.004). On the lower panel are IL2RA 
(HPA054622; q = 0.003) and LNPEP (HPA043642; q = 0.003); hence, all revealed higher levels in controls compared with the combined UC and CD 
cases. B, When comparing CD (n = 49) and controls (n = 50), antibodies against LACC1 (HPA040150; q = 0.002) and LNPEP (HPA043642; q = 0.008) 
revealed higher protein levels in controls, whereas levels of SAA (HPA059733; q = 0.002) were higher in CD patients. C, When comparing UC (n = 51) 
with controls (n = 50), the levels for CNTF (HPA046534; q = 0.008) and LPXN (HPA061441; q = 0.008) were all lower in UC cases. The presented data 
are for normalized MFI values.
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differed between CD patients with complicated disease beha-
vior, that is, stricturing (B2) or penetrating (B3) disease, and 
patients with ulcerative colitis. The performance characteristics 
(tCV, bCV, and rho) of the significantly altered antibodies can 
be found in Supplementary Table 2.
Multivariate analysis
We used a multivariate sPLS model to identify signa-
tures of proteins differentially expressed between different 
groups of patients and healthy controls. Our sPLS modeling 
resulted in fitted sPLS models, together with optimal numbers 
of components (latent variables for the PLS discriminant anal-
ysis) and optimal numbers of proteins used for each model. 
Most proteins identified in univariate analysis as being sig-
nificantly altered in IBD, CD, and UC vs controls, and in CD 
vs UC, were also identified in the discriminant sPLS analyses 
(Supplementary Table 3). In contrast to the univariate analy-
ses, differentiating protein expression signatures between CD 
subtypes (colonic = L2, ileal = L1/L3, or complicated disease 
behavior  =  B2/B3) and UC were identified in the multivari-
ate analyses (Supplementary Table  3). Differently expressed 
protein signatures were also observed when UC patients with 
active disease were compared with those in remission, but no 
differences were observed when CD patients were stratified by 
disease activity (Supplementary Table 3). Figure 4 shows sPLS 
scores plots to visualize how the found biosignatures could 
classify the different disease classes in our data.
To assess the predictive accuracy of our model, hit rates 
were collected, and their significance assured that a leave-one-
out cross-validation approach could be applied. The hit rates 
and their respective resampling significances, obtained in our 
sPLS analyses, are shown in Supplementary Table 4. All com-
parisons resulted in significant resampling P values, but the 
observed hit rates for CD vs UC and colonic CD vs UC were 
comparatively low.
LACC1-Specific Analyses
A primary finding from the univariate and multivari-
ate analyses is that the protein laccase (multicopper oxidore-
ductase) domain containing 1 (LACC1; previously known 
as C13orf31) was differentially abundant in the serum sam-
ples from IBD patients compared with healthy controls. 
LACC1 has been recently characterized as a novel player in 
IBD and inflammation, involved in the control of  macro-
phage immunometabolic function in general, and we sought 
to further investigate our results. In the assays, LACC1 
was detected by 2 different antibodies (HPA040150 and 
HPA061537), which are raised toward 2 independent epi-
topes, located at the N-terminal and C-terminal portions of 
the target protein, respectively. The obtained serum profiles 
TABLE  3. Antibodies and Corresponding Proteins With Differential Abundance in Patients With Crohn’s Disease 
Compared With Patients With Ulcerative Colitis in Sample Sets IBD 1 and IBD 2, Identified by Univariate Analyses
Gene Antibody
IBD 1
P
IBD 2
P
Meta
P
Meta
q
SAA HPA059733 8.75E-02 1.21E-01 3.45E-05 1.24E-02
CREB5 HPA057734 2.83E-02 3.63E-02 2.04E-04 3.68E-02
FIGURE 2. (Continued)
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from these 2 antibodies correlated with a Spearman rho of 0.6 
(Supplementary Fig. 2), indicating concordant selectivity for 
a common target in the matrix of  human serum. The anti-
body HPA040150 was further validated as it shows a stronger 
association when comparing IBD and CD patients with con-
trols. Western blot analyses of  protein extracts from LACC1-
overexpressing cells established that HPA040150 binds to 
denatured LACC1 (Supplementary Fig.  3A). In addition, 
epitope mapping analyses of  the antibody were performed. 
Three epitopes were identified (Supplementary Fig. 3B), and 
a Uniprot BLAST search (100% identity and E value thresh-
old  <  10) showed that only LACC1 matches the peptides. 
Finally, immuno-capture mass spectrometry analysis was con-
ducted and confirmed that HPA040150 enriched its intended 
target LACC1 from serum (Supplementary Fig. 3C).
DISCUSSION
The identification of  susceptibility risk variants has 
afforded limited success in translating genetic discover-
ies to enhanced knowledge of  the serum proteome in IBD. 
Exploiting gene content from known IBD risk loci, we imple-
mented a screen of  the IBD risk proteome for the identification 
of  serum targets eventually suitable for inclusion in follow-up 
biomarker discovery efforts. For this purpose, we took advan-
tage of  the HPA large antibody repository and an affinity pro-
teomic approach, which allowed the identification of  proteins 
showing differential abundance in healthy vs IBD serum, and 
in serum from different subgroups of  patients. Although these 
proteins mostly relate to neutrophil, T-cell, and B-cell activa-
tion and function, our strategy shows that multiplexed bead-
based antibody array approaches may be successfully adopted 
to exploit existing genetic information for the delineation of 
targeted proteomic studies. However, inherent limitations in 
this study should be noted and eventually avoided in follow-up 
investigations: (1) the inclusion of  patients with a long disease 
duration may have introduced bias due to disease history; (2) 
there is a lack of  data on endoscopic activity that may have 
been correlated with specific protein profiles; (3) acknowledg-
ing the exploratory nature of  the our study, assays for known 
and expected protein signatures may not be reported; and 
(4) instead of  using fully validated assays, the multiplexed 
approach may offer only insufficient analytical sensitivity 
and specificity, hence reducing the number of  risk candidates 
identified in serum. Another important limitation is that we 
FIGURE 3. Candidate proteins: CD vs UC. The boxplots show the proteins that differed between CD and UC patients in the 2 study sets, IBD 1 and 
IBD 2, with q < 0.05. Levels of (A) SAA (HPA059733; q = 0.012) and (B) CREB5 (HPA057734; q = 0.037) were both higher in CD patients. The presented 
data are for normalized MFI values.
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were only able to measure 204 proteins out of  1438 proteins 
encoded in 104 out of  the 163 risk loci. Although our analyses 
were based on an unbiased approach, in targeting all proteins 
encoded at IBD risk loci, we were not able to define the exact 
mechanisms underlying specific predictive protein profiles or 
to establish a relationship between individual single nucleotide 
polymorphisms (SNPs) and protein expression levels (protein 
quantitative trait loci [pQTLs]), as this requires large-scale 
samples and analytical techniques that ensure exact relative 
measurement of  protein levels.
Previously, only a small number of studies have aimed to 
identify serum proteins associated with IBD,25–27 but these have 
been in general limited to a small number of selected targets. In 
recent years, some initiatives to increase our understanding have 
been initiated. Di Narzo et al. reported novel aging-associated 
proteomic traits and proteomic traits in Crohn’s disease patients, 
FIGURE 4. sPLS scores plots of comparisons between CD patients and subgroups of CD patients, ulcerative colitis patients, and healthy controls. 
The sPLS scores plots visualize how the found biosignatures could classify CD patients and subgroups of CD patients, ulcerative colitis patients, and 
healthy controls, respectively. Abbreviations: cCD, colonic CD; iCD, ileal CD; CD_B1, nonstricturing, nonpenetrating CD; CD_B23, stricturing or pene-
trating CD; UC_AD, UC with active disease; UC_nonAD, UC with nonactive disease.
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corresponding to 41 distinct genes, that were significantly influ-
enced by SNP genotypes in cis.28 The HPA, aiming at generating 
and applying antibodies directed toward every human protein, 
represents another recent initiative. The project has been built 
on the systematic generation of antibodies through a predefined 
pipeline.29–32 Here we took advantage of this large antibody 
repository to assay serum expression levels of proteins translated 
from IBD-related risk loci9 and proteins related to inflammation 
including neutrophil activation. Based on this approach, we 
identified a number of proteins that appear to be differentially 
expressed in sera from IBD patients compared with healthy con-
trols. Among the top-ranking proteins, we found targets related 
to cytokine signaling (IL2RA33), immune-metabolic regulation 
and reactive oxygen species production (LACC134), antigen pre-
sentation (LNPEP35), T-cell regulation (CARD11,36 BTNL2,37 
and IFNG,38), B-cell signaling (LPXN), and neurotransmitter 
synthesis (CNTF39). To our knowledge, only a few of these pro-
teins, such as CNTF39 and LNPEP,35 have been known to be 
present in sera. LACC1, whose serum expression has not been 
previously studied, was identified to be differentially expressed 
in IBD patients compared with healthy controls. Genetic vari-
ation in the LACC1 gene has been associated with IBD, lep-
rosy, and systemic and nonsystemic juvenile idiopathic arthritis 
(JIA),9, 40–42 whereas the corresponding protein product has been 
recently characterized as a master regulator of macrophage 
immune-metabolic function.40 In the present study, we observed 
reduced serum LACC1 levels in IBD patients (primarily CD 
patients) compared with controls. Notably, reduced LACC1 
expression has been reported to parallel the finding of hypo-
morphic (reduced function) LACC1 gene variants, which are 
associated with increased risk of CD.40
Lower abundance of LNPEP, an aminopeptidase involved 
in antigen presentation,43 was also observed in CD patients 
compared with healthy controls. Interestingly, LNPEP comes 
from the IBD risk locus containing also the endoplasmic retic-
ulum aminopeptidases 1 and 2 (ERAP1 and ERAP2), which 
are both involved in the regulation of innate immune response44 
and have well-established roles in IBD and other auto-inflam-
matory diseases.9, 45 Lower levels of serum expression were 
observed for CNTF and LPXN in UC cases compared with 
controls. CNTF is believed to be involved in the recruitment 
of macrophages,46 whereas LPXN has been reported to have 
an inhibitory role in B-cell function47 and to be involved in the 
development of colorectal cancer in UC patients.48
Interestingly, the results from specific antibodies for an 
epitope shared by 2 isoforms of the SAA, namely A1 and A2, 
point to increased abundance of the SAA protein in serum 
from CD vs UC patients. This finding is supported by a pre-
viously reported correlation between serum SAA levels and 
endoscopic activity in patients with CD.49 Similarly, increased 
abundance of antibodies toward CREB5, a transcription factor 
regulating a variety of cellular responses,50 was observed in CD 
patients when compared with UC patients. This observation 
is consistent with the previously observed genetic association 
between CREB5 and CD, but not UC,9 and the earlier reported 
upregulation of CREB expression in peripheral blood mono-
nuclear cells of CD patients.51, 52
By implementing an sPLS model, we were able to iden-
tify signatures (ie, combinations) of proteins associated with 
IBD and its subtypes CD and UC. Based on these signatures, a 
predictive accuracy of 0.76–0.83 was observed when compared 
with healthy controls. The accuracy of our model dropped when 
different subtypes of IBD were compared against each other, 
even though our protein signatures remained significant, indi-
cating that the found protein signatures were truly discrimina-
tive for all tested comparisons. Interestingly, a better accuracy 
was observed for serum profiles from ileal rather than colonic 
CD, when these were compared with UC profiles. This observa-
tion may add further support to recent genetic data, indicating 
that the genetic distance between ileal CD and UC is actually 
larger than that between colonic CD and UC.4 Differentially 
expressed signatures of proteins were also observed between CD 
patients with complicated disease behavior (stricturing [B2] or 
penetrating disease [B3]) and CD patients with nonstricturing, 
nonpenetrating disease (B1), and with UC patients. This finding 
may seem contrary to that of Cleynen et al., who reported little 
or no genetic association with disease behavior.4 However, our 
findings might have been biased by differences in other pheno-
typic characteristics such as disease location and age at onset.
In conclusion, we took advantage of a large repository 
of antibodies to exploit genetic information from IBD risk loci 
to identify disease-associated serum profiles. Among others, we 
report interesting results for LACC1, a novel immune player 
in IBD that shows downregulated expression in CD patients. 
A number of additional candidate proteins have the potential 
to be prioritized as selected targets in future biomarker discov-
ery efforts in IBD.
SUPPLEMENTARY DATA
Supplementary data are available at Inflammatory Bowel 
Diseases online.
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